Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) has been assigned an average recommendation of “Hold” from the eight research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback